Compare SLI & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLI | SGP |
|---|---|---|
| Founded | 1998 | 2019 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 932.9M |
| IPO Year | 2011 | N/A |
| Metric | SLI | SGP |
|---|---|---|
| Price | $4.00 | $24.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $5.25 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 1.8M | 48.8K |
| Earning Date | 05-11-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.49 | $20.15 |
| 52 Week High | $6.40 | $30.56 |
| Indicator | SLI | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 52.93 | 49.76 |
| Support Level | $3.97 | $20.95 |
| Resistance Level | $4.08 | $26.55 |
| Average True Range (ATR) | 0.23 | 1.38 |
| MACD | 0.03 | 0.07 |
| Stochastic Oscillator | 47.83 | 60.64 |
Standard Lithium Corp is engaged in the exploration and development of lithium brine properties in the United States. The company the company's flagship projects are located in the Smackover Formation, a world-class lithium brine asset, focused in Arkansas and Texas. It is also Standard Lithium is advancing the South West Arkansas project, a greenfield project located in southern Arkansas, and strengthening lithium brine prospects in East Texas. Its other project comprises the Lanxess Property Project; and California Properties. The technologies used for the projects are : Direct Lithium Extraction; Demonstration Plant; SiFT; Lithium Sulfide; and Aqualung.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.